Amino Inc. is a San Francisco-based online platform that assists users in navigating the complexities of the U.S. healthcare system. The platform allows patients to search for doctors based on various conditions, procedures, and specialties, helping them compare experiences and make informed healthcare choices. Additionally, Amino provides personalized matches for in-network facilities and offers a concierge service for booking appointments with qualified doctors. The company, originally known as Pare Labs, Inc., was incorporated in 2013 and adopted its current name in May 2014.
Antheia is a biotechnology company focused on developing plant-inspired medicines through innovative synthetic biology techniques. By utilizing whole-cell engineering, the company reconstructs complex molecules in yeast, allowing for the cost-effective production of next-generation pharmaceuticals. Antheia's approach combines synthetic biology, informatics, and fermentation technology to extract beneficial molecules from plants, ultimately creating active pharmaceutical ingredients. This enables healthcare organizations to offer patients natural and healthier medication options.
SeLux Diagnostics, Inc. is focused on advancing antibiotic susceptibility testing and infectious disease diagnostics through its innovative phenotyping platform. Founded in 2014 and located in Charlestown, Massachusetts, the company employs a unique synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing. This platform significantly improves the accuracy and timeliness of diagnosing infections, enabling healthcare providers to prescribe targeted and personalized antibiotic therapies. By facilitating informed treatment decisions, SeLux Diagnostics aims to enhance patient care, save lives, and improve overall health outcomes in hospital settings.
Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that focuses on developing innovative solutions for carotid artery disease. The company specializes in transcarotid artery revascularization (TCAR), a minimally invasive approach designed to reduce the risk of stroke during surgical interventions. Its product lineup includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery and allows for temporary blood flow reversal to protect the brain. Additionally, the ENROUTE Transcarotid Stent System is a self-expanding stent backed by clinical evidence supporting its safety outcomes. Other offerings include the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire for guiding interventional devices. Founded in 2007, Silk Road Medical aims to improve patient care through collaboration with vascular specialists and ongoing innovation in vascular therapies.
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.
Lexicon Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing pharmaceutical products aimed at treating various human diseases, including those related to immunology, metabolism, cardiology, and ophthalmology. The company's pipeline features several drug candidates, such as LX1031, which has completed Phase II trials for irritable bowel syndrome; LX4211, also in Phase II trials for type 2 diabetes; LX2931, currently undergoing Phase II trials for rheumatoid arthritis; and LX1032, which has completed Phase II trials for carcinoid syndrome symptoms. Additionally, the company is developing LX7101 for glaucoma in preclinical stages and is working on LX9211 for neuropathic pain, along with sotagliflozin for heart failure and type 1 diabetes. Lexicon has formed strategic alliances and collaborations with various pharmaceutical companies and research organizations to enhance its drug discovery and development capabilities.
Centogene AG is a leading genetic biotechnology company based in Rostock, Germany, specializing in genetic and biochemical diagnostic testing for rare hereditary disorders. The company offers a range of services to support the medical community, including genetic counseling, newborn screening, and biomarker analysis for lysosomal storage disorders. Centogene has developed a comprehensive rare disease platform that integrates epidemiologic, phenotypic, and genetic data, along with a biobank of blood samples, to aid in patient diagnosis and treatment. Additionally, the company collaborates with pharmaceutical partners to provide services such as patient recruitment, epidemiological insights, and biomarker discovery. Its diagnostic services are accessible through healthcare providers, facilitating targeted genetic sequencing for patients with various genetic disorders. With operations in multiple countries, including the United States and the United Arab Emirates, Centogene aims to improve awareness and treatment options for patients with rare diseases globally.
Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer, particularly in the fields of hematology and oncology. Its lead candidate, momelotinib, is a selective JAK1, JAK2, and ACVR1 inhibitor that has been evaluated in two Phase 3 trials for myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, currently undergoing two Phase 1/2 clinical trials to explore its potential as a monotherapy and in combination with other therapies. Additionally, Sierra is developing SRA141, a small molecule inhibitor of cell division cycle 7 kinase, which is in preclinical research stages. Founded in 2003 and headquartered in Vancouver, Canada, Sierra Oncology retains global commercialization rights for its product candidates and aims to achieve successful registration and commercialization of its innovative therapies targeting the DNA Damage Response network.
Choice Health at Home, LLC is a Texas-based company that specializes in delivering home health, hospice, rehabilitation, and personal care services. Founded in 2007 and headquartered in Tyler, Texas, the organization focuses on providing rehabilitation services directly in patients' homes, ensuring that individuals receive the care they need in a comfortable and familiar environment. Through its comprehensive range of services, Choice Health at Home aims to enhance the quality of life for its clients while supporting their health and recovery in a personalized manner.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Platelet BioGenesis is a biotechnology company focused on producing donor-independent human platelets from pluripotent stem cells for clinical use. Founded in 2014 and based in Cambridge, Massachusetts, the company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. Platelet BioGenesis distributes these bioreactor-produced platelets to hospitals and blood banks, aiming to provide a reliable source of platelets for patients worldwide. By specializing in the fields of platelets and drug discovery, the company is addressing critical needs in the medical community related to blood supply and treatment options.
4D Pharma is a biotechnology company based in Leeds, United Kingdom, specializing in the research, development, and production of live biotherapeutic products. Founded in 2014, the company has established a proprietary platform called MicroRx, which identifies novel bacteria with therapeutic effects for various diseases. Its product pipeline includes treatments for conditions such as irritable bowel syndrome, pediatric Crohn's disease, and several solid tumors, including pancreatic cancer. Additionally, 4D Pharma is developing products targeting respiratory issues like asthma and COVID-19, as well as therapies for neurodegenerative diseases. The company has initiated collaborations, including a clinical trial with Merck & Co. to evaluate the efficacy of combining its product MRx0518 with Keytruda in cancer patients. With a total of 15 therapeutic programs, 4D Pharma aims to advance its innovative treatments, with two currently in patient trials and plans to initiate more in the near future.
Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.
Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company specializes in developing and commercializing ReActiv8, an implantable neurostimulation system aimed at treating chronic low back pain. This innovative therapy is designed to restore control to the muscles that stabilize the lumbar spine, addressing a significant unmet need in the healthcare market. By collaborating with scientists and clinical experts, Mainstay Medical focuses on delivering effective solutions for patients suffering from debilitating pain, ultimately enhancing their quality of life.
Immunocore Limited is a biotechnology company specializing in the discovery and development of innovative T cell receptor-based therapeutics aimed at treating cancer, viral diseases, and autoimmune disorders. Founded in 1999 and headquartered in Abingdon, United Kingdom, with an additional office in Conshohocken, the company has developed a proprietary technology platform that enables the engineering of T cell receptors (TCRs) linked to antibody fragments. This expertise has led to the advancement of IMCgp100, a bi-specific immunotherapeutic currently undergoing clinical trials for metastatic melanoma. Immunocore's focus on addressing diseases with significant unmet medical needs underscores its commitment to advancing novel treatment options.
Greenbrook TMS Inc., together with its subsidiaries, operates a network of outpatient mental health services centers in the United States. It offers transcranial magnetic stimulation therapy, an FDA-cleared non-invasive therapy that provides electromagnetic stimulation to brain regions associated with mood regulation for the treatment of major depressive disorder and other mental health disorders. The company operates approximately 121 treatment centers in the United States. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada.
Nature's Fynd develops a protein production platform from extremophile organisms for consumer and industrial applications. The company was formerly known as Sustainable Bioproducts, Inc. Nature's Fynd was incorporated in 2016 and is headquartered in Chicago, Illinois with an additional office in Bozeman, Montana.
RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
SpendMend helps leading healthcare organizations nationwide discover the full impact of financial leakage upon their organization. As the healthcare expert in audit recovery and spend visibility, SpendMend has perfected the process of holistically analyzing complex spend data to help an organization shed light upon ubiquitous and pesky financial leakage. SpendMend helps recover financial leakage and partners with clients to identify control gaps harboring financial leakage and improve spend visibility.
ReMed is a brain injury rehabilitation company.
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.
It was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Enable Injections, LLC develops a disposable body-worn bolus injector to deliver high viscosity/volume payloads to the subcutaneous tissue. The company’s system uses standard vial, syringe, or cartridge container closure; and automatically mixes lyophilized solutions. Its drug delivery system’s transfer package automatically warms the drug, and enables user to insert the container into the system, place the injector on the skin, and press the central button, as well as know the progress of the delivery through its viewing window, and then dispose the device. It also offers partial or multi-vial/syringe transfer systems for filling its LVWIs. The company was founded in 2010 and is based in Cincinnati, Ohio.
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.
Epic Healthcare Staffing is a diversified national provider of staffing services to the healthcare and bio-pharmaceutical industries.
Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.
GenapSys, Inc. develops innovative DNA sequencing technologies for applied genomic testing and medical sequencing. The company's primary product, the GenapSys Sequencer, utilizes electrical-based detection for single nucleotide incorporations, facilitating sequencing in various laboratory settings and automating clonal amplification. GenapSys offers solutions for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. Additionally, the company seeks to collaborate with local health agencies and researchers to enhance access to sequencing insights, particularly for controlling and mitigating outbreaks. The compact and portable nature of the sequencer allows it to operate from standard power sources, making it suitable for deployment in hospitals, airports, and public transportation hubs to provide rapid results for virus samples. Founded in 2010, GenapSys is headquartered in Redwood City, California.
Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.
LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and is uniquely suited for the treatment of children as well as adults.
Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. Utilizing its proprietary XeriSol and XeriJect technology platforms, the company delivers highly concentrated, liquid-stable formulations of peptides, small molecules, and proteins through various delivery methods, including syringes and auto-injectors. Xeris Biopharma's lead product is Gvoke, a ready-to-use glucagon for treating severe hypoglycemia, while its other products include Keveyis, the first FDA-approved treatment for primary periodic paralysis, and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. The company is also advancing several product candidates in clinical trials, targeting conditions in endocrinology, neurology, and gastroenterology. Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma aims to improve patient care by providing easier-to-use therapies that enhance treatment outcomes.
SGI-DNA provides a variety of synthetic genomic solutions to advance your research. Our comprehensive suite of genomic services will allow you to discover, design, and build the sequences you need. We are committed to reducing barriers associated with DNA synthesis and sequence analysis by leveraging the technology developed at the J. Craig Venter Institute and Synthetic Genomics, Inc. SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), was founded in 2013 and is headquartered in La Jolla, CA. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services. SGI-DNA is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers.
MolecuLight is a company focused on developing non-invasive optical imaging technology for the healthcare sector, specifically targeting wound care. Their portable handheld devices enable real-time visualization and analysis of bacteria, which is critical for accurate wound assessment and diagnosis. Unlike traditional methods that rely on standard white light visualization, MolecuLight's technology provides unique bacteriological information, allowing medical practitioners to make informed decisions about treatment options. This innovation aims to improve patient outcomes by facilitating timely and precise diagnosis in the global wound care market, where there is a pressing medical need.
ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for the management of acute pain. The company's lead product is DSUVIA, a sublingual tablet containing sufentanil, designed for the treatment of moderate-to-severe acute pain. In addition to DSUVIA, AcelRx offers ZALVISO, a pre-programmed patient-controlled analgesia system that enables hospital patients to self-administer sufentanil for pain management. The company also develops other products, including the Sufentanil NanoTab PCA system for post-operative pain and Sufentanil NanoTab therapies for cancer pain management. Established in 2005 and headquartered in Redwood City, California, AcelRx serves a diverse range of stakeholders, including patients, healthcare providers, and regulatory bodies.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Summit Healthcare REIT is currently focused on investing in senior housing real estate
Evolus, Inc. is a performance beauty company based in Newport Beach, California, specializing in medical aesthetic products for physicians and their patients in the United States. The company's flagship product, Jeuveau, is a proprietary formulation of purified botulinum toxin type A designed to temporarily improve the appearance of moderate to severe glabellar lines, commonly referred to as frown lines. Evolus targets the self-pay aesthetic market, offering solutions that cater to the needs of aesthetic physicians and their patients. The company has positioned itself to compete with established products in the market by emphasizing the performance characteristics of its formulations. With a customer-centric approach, Evolus aims to provide innovative options for aesthetic treatments and expand choices available in the growing facial aesthetics sector.
Continuing Healthcare Solutions is a provider of long-term care and healthcare services that focuses on delivering exceptional care while treating residents with dignity and respect. The company offers a comprehensive range of services, including assisted living, skilled nursing care, rehabilitation services, memory care, behavioral health, respiratory care, wound management, and hospice care. By prioritizing the hiring, training, and retention of qualified healthcare professionals, Continuing Healthcare Solutions aims to establish itself as a preferred provider in its communities, ensuring that residents receive compassionate and quality care.
AliveCor, Inc. is a technology company that develops digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile devices. Its flagship product, KardiaMobile, provides instant detection of common heart arrhythmias and allows users to track blood pressure and weight, as well as store recorded EKGs. The company also offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed readings with their healthcare providers. Additionally, AliveCor has introduced KardiaCare, a digital health subscription service that facilitates the management of heart health at home. Founded in 2010 and headquartered in Mountain View, California, AliveCor is recognized for its pioneering efforts in using machine learning techniques to enhance cardiac care and improve early detection of conditions such as atrial fibrillation.
Nevakar Inc. is a pharmaceutical company based in Bridgewater, New Jersey, established in 2015. The company specializes in developing innovative ophthalmic and injectable products, aiming to enhance existing FDA-approved molecules to meet unmet clinical and commercial needs. Nevakar's operations are supported by a state-of-the-art research and development infrastructure located in the New Jersey Center of Excellence, coupled with a knowledgeable management and leadership team that guides its intensive research and clinical efforts.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
QuVa Pharma will be the industry’s leading 503B platform and the partner of choice for compliance-oriented healthcare facilities looking to ensure quality, safe and consistent supply of medications.
QuVa Pharma will achieve this through its commitment to innovation, by operating from superior facilities under stringent cGMP adherence, and by attracting individuals absolutely committed to quality and who bring deep sterile injectable manufacturing expertise.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.
Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. Utilizing its proprietary XeriSol and XeriJect technology platforms, the company delivers highly concentrated, liquid-stable formulations of peptides, small molecules, and proteins through various delivery methods, including syringes and auto-injectors. Xeris Biopharma's lead product is Gvoke, a ready-to-use glucagon for treating severe hypoglycemia, while its other products include Keveyis, the first FDA-approved treatment for primary periodic paralysis, and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. The company is also advancing several product candidates in clinical trials, targeting conditions in endocrinology, neurology, and gastroenterology. Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma aims to improve patient care by providing easier-to-use therapies that enhance treatment outcomes.
VitalConnect specializes in wearable biosensor technology aimed at enhancing patient monitoring both in hospitals and remotely. The company utilizes its expertise in biomedical engineering, data analytics, and chip design to develop products that continuously monitor vital signs through an adhesive patch. These innovations include the Vista Solution, which provides healthcare professionals with 24/7 access to patient health data via an online portal, tracking 11 vital signs and offering predictive analytics. The VitalPatch biosensor specifically measures critical parameters such as EKG, heart rate, respiratory rate, and body temperature, facilitating immediate responses to urgent health situations. By combining these technologies, VitalConnect's solutions improve patient mobility and comfort while enabling clinicians to optimize treatment through comprehensive patient insights, ultimately leading to better health outcomes and reduced economic burdens.
Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.
Castle Biosciences, we focus on addressing this gap. We work with leading cancer institutions to in-license proprietary technologies and complete development and validation. The ultimate goal is to make these proven tests available to all individuals afflicted with a rare cancer.
Cerapedics, Inc. is an orthobiologics company based in Westminster, Colorado, specializing in the development and commercialization of its proprietary small peptide technology platform, specifically the biomimetic peptide molecule known as P-15. The company focuses on creating innovative solutions for spinal applications and orthopedic procedures. Its primary offerings include i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural bone healing process, and i-FACTOR+ MATRIX for surgical implantation. Founded in 2000, Cerapedics aims to provide safer and more predictable bone formation options compared to traditional bone growth factors, thereby enhancing the effectiveness of spinal fusion surgeries and other orthopedic treatments.
Reata Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for serious and life-threatening diseases by targeting key molecular pathways related to cellular metabolism and inflammation. The company is advancing several clinical trial programs, including Phase III trials for bardoxolone methyl, aimed at treating chronic kidney disease associated with Alport syndrome and pulmonary arterial hypertension linked to connective tissue disease. Additionally, omaveloxolone is undergoing Phase II trials for Friedreich’s ataxia, while other studies focus on various types of chronic kidney disease. Reata is also developing RTA 901 for neurological disorders and RORgT inhibitors for autoimmune and inflammatory diseases, currently in preclinical development. The company has strategic partnerships with Kyowa Kirin for the commercialization of bardoxolone in select Asian markets and with AbbVie for research and development of Nrf2 activators. Founded in 2002 and originally named Reata Discovery, Inc., the company is headquartered in Plano, Texas.
Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.
Conformis, Inc. is a medical technology company based in Billerica, Massachusetts, specializing in the development, manufacturing, and sale of personalized joint replacement implants and instruments. Utilizing its proprietary iFit® Image-to-Implant® technology platform, Conformis creates individually sized and shaped implants tailored to fit each patient's unique anatomy. The company's product offerings include various knee replacement systems, such as iTotal CR, iTotal PS, iDuo, and iUni, as well as the Conformis Hip System and customized single-use instrumentation known as iJigs. Conformis markets its products primarily to hospitals and ambulatory surgical centers through a combination of its sales force, independent representatives, and distributors in multiple countries, including the United States and several European and Asian markets. The company emphasizes superior clinical outcomes and patient satisfaction compared to traditional off-the-shelf implants.
Eiger BioPharmaceuticals is a late-stage biopharmaceutical company based in Palo Alto, California, dedicated to developing targeted therapies for rare and ultra-rare diseases. The company’s lead product candidate, Lonafarnib, is an orally bioavailable small molecule currently undergoing Phase 3 clinical trials for the treatment of hepatitis delta virus (HDV) infection. Eiger's pipeline also includes Lambda, which is in Phase 2 trials and targets type III interferon receptors for HDV, as well as Lonafarnib for progeria and progeroid laminopathies. Additionally, the company is developing Avexitide, which has completed Phase 2 trials for post-bariatric hypoglycemia and is also in Phase 2 for congenital hyperinsulinism. Eiger's focus is on addressing high unmet medical needs in serious diseases where no approved therapies currently exist.
Veran Medical Technologies is a medical device company that specializes in developing minimally invasive devices for interventional oncology procedures. Headquartered in Saint Louis, Missouri, the company offers a range of products designed to assist physicians in diagnosing diseases and delivering therapies effectively. Its key offerings include the SPiNView thoracic navigation system, which facilitates biopsies of solitary pulmonary nodules for early lung cancer detection, and the ig4 IR System, an electromagnetic platform that aids in various procedures such as biopsies and ablations. Additionally, Veran provides tools like the SPiNPerc hybrid diagnostic device and vTrack 2.0 Instruments, which enhance the precision of lung procedures. The company's innovative technology generates dynamic 3D maps of respiratory airways, allowing for optimal planning and navigation during diagnostic processes. Established in 2003, Veran Medical Technologies focuses on improving patient outcomes through advanced image-guided medical devices.
Bi02 Medical, Inc. designs, develops, manufactures, and commercializes medical devices for clinical needs. The company offers Angel Catheter, an inferior vena cava (IVC) filter for the protection of prophylactic pulmonary embolism, and access to the central venous system in critically ill patients. It sells its products through distribution partners worldwide. Bi02 Medical, Inc. was formerly known as BiO2 Medical Inc. The company was founded in 2006 and is based in San Antonio, Texas with a research and development, and manufacturing facility in Golden, Colorado.
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.
Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes, primarily in Europe. Founded in 1996, the company develops advanced implantable CGM products, including Eversense and Eversense XL, which monitor glucose levels for up to 90 and 180 days, respectively. Using innovative fluorescence sensing technology, these systems are designed to provide high accuracy and stability throughout their extended sensor life. The company aims to empower people with diabetes to manage their condition more effectively and confidently through its CGM solutions, which also include a smart transmitter and a mobile app. A significant portion of Senseonics' revenue is generated from markets outside the United States.
Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide.
Ignyta was incorporated in 2011 and operates in San Diego, California.
Monteris Medical develops and markets advanced medical devices for minimally invasive neurosurgery, focusing on the treatment of brain diseases. Their flagship product, the NeuroBlate System, utilizes MRI-guided laser thermotherapy for the precise ablation of pathological brain lesions, including both primary and metastatic tumors. This innovative system allows neurosurgeons to deliver focused laser energy directly to tumors while minimizing damage to surrounding healthy tissue, offering real-time control and visualization during procedures. Monteris Medical also provides stereotactic anchoring devices for accurate image-guided trajectory alignment and AtamA stabilization systems for MR-based procedures requiring head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, with additional offices in Minneapolis and Winnipeg, the company distributes its products through sales representatives to neurosurgeons across the United States. Formerly known as AutoLITT, Monteris Medical has established itself as a leader in the development of technologies aimed at improving the treatment of brain cancer.
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of therapies that target microRNAs to address various diseases. Its primary product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, a severe kidney condition, and RGLS4326, an anti-miR aimed at miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. In addition to these lead candidates, Regulus is cultivating a preclinical pipeline that includes RGLS5579, targeting miR-10b, as well as programs focused on Hepatitis B and Non-Alcoholic Steatohepatitis. Founded in 2007, Regulus Therapeutics is headquartered in San Diego, California.
Omeros Corporation is a Seattle-based biopharmaceutical company engaged in the discovery, development, and commercialization of small-molecule and protein therapeutics. The company focuses on large-market and orphan indications, particularly targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. Omeros offers OMIDRIA, a product used during cataract surgery in the United States. Its clinical pipeline includes narsoplimab, a monoclonal antibody in Phase III trials for various conditions, including hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. Other clinical programs involve treatments for opioid and nicotine addiction, as well as compulsive disorders. Preclinical efforts include developing therapies for paroxysmal nocturnal hemoglobinuria and exploring a range of G protein-coupled receptors for various disorders. Founded in 1994, Omeros is committed to addressing significant unmet medical needs through its innovative therapeutic approaches.
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.
Nuvectra, focus not only on what our devices do, but also on reducing their complexity for clinicians and patients. We are committed to developing products with intelligent innovations and technologies that provide improved outcomes and long-term solutions for our customers.
Superior Biologics is a provider of intravenous and injectable medications tailored for patients with chronic disorders. The company operates primarily in the tri-state area of New York, New Jersey, and Connecticut, while also extending its services to additional states based on pharmacy licensure. Committed to delivering cost-effective and patient-specific care, Superior Biologics focuses on meeting the individual needs of patients and their families through personalized service. The company is headquartered in Hawthorne, New York, and employs highly qualified professionals to ensure optimal therapeutic outcomes for its patients.
Bi02 Medical, Inc. designs, develops, manufactures, and commercializes medical devices for clinical needs. The company offers Angel Catheter, an inferior vena cava (IVC) filter for the protection of prophylactic pulmonary embolism, and access to the central venous system in critically ill patients. It sells its products through distribution partners worldwide. Bi02 Medical, Inc. was formerly known as BiO2 Medical Inc. The company was founded in 2006 and is based in San Antonio, Texas with a research and development, and manufacturing facility in Golden, Colorado.
Omeros Corporation is a Seattle-based biopharmaceutical company engaged in the discovery, development, and commercialization of small-molecule and protein therapeutics. The company focuses on large-market and orphan indications, particularly targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. Omeros offers OMIDRIA, a product used during cataract surgery in the United States. Its clinical pipeline includes narsoplimab, a monoclonal antibody in Phase III trials for various conditions, including hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. Other clinical programs involve treatments for opioid and nicotine addiction, as well as compulsive disorders. Preclinical efforts include developing therapies for paroxysmal nocturnal hemoglobinuria and exploring a range of G protein-coupled receptors for various disorders. Founded in 1994, Omeros is committed to addressing significant unmet medical needs through its innovative therapeutic approaches.
Aratana Therapeutics, Inc. is a pet therapeutics company based in Leawood, Kansas, that specializes in the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. The company’s product portfolio includes a range of therapeutics such as NOCITA, which provides post-operative analgesia for dogs, ENTYCE for appetite stimulation, and GALLIPRANT for managing pain and inflammation due to osteoarthritis. Additionally, Aratana is developing innovative treatments, including a bupivacaine liposome injectable suspension for cats and various therapeutic candidates aimed at addressing conditions like atopic dermatitis and feline herpes virus. Aratana also has collaborations with other companies, including Elanco Animal Health, to further enhance its product offerings. Founded in 2010, Aratana Therapeutics focuses on delivering high-quality medicines to meet the unmet needs of companion animal care.
MDRejuvena is dedicated to and passionate about providing products that rejuvenate, enhance, and maintain skin health for the patients of physicians and skincare professionals worldwide. It specializes in the fields of fitness, healthcare, and wellness. It was founded in 2015 and headquartered in San Diego, California.
Zyga Technology, Inc. is a medical device company focused on the research, design, development, and commercialization of minimally invasive solutions for lumbar spine conditions. The company offers the SImmetry Sacroiliac Joint Fusion System, which addresses various issues such as sacroiliac joint disruptions and degenerative sacroiliitis. Additionally, Zyga is developing the Glyder Facet Restoration System, an investigational device aimed at treating chronic facetogenic pain. Founded in 2008 and based in Minnetonka, Minnesota, Zyga Technology combines a skilled team of engineers, marketing professionals, and management with extensive experience in the spine industry. As of December 31, 2017, Zyga operates as a subsidiary of RTI Surgical, Inc.
Continuum Health Alliance, LLC ("Continuum") is a regional healthcare management company founded in 1998 by nationally-renowned pediatrician John M. Tedeschi, MD. Continuum offers operational oversight and optimizes business processes, enabling physician groups and hospitals to better serve their patients. The Company's comprehensive service portfolio is built on five pillars. Continuum offers administrative solutions, financial services, revenue cycle management, information technology, and population management services, which addresses new governmental guidelines and healthcare initiatives. Continuum also collaborates with hospitals to create and manage medical group networks, hospitalist programs, and innovative hospital-based programs; and helps medical providers navigate and respond to the regulatory requirements mandated by America's health care reform legislation. The Company presently oversees an aggregate client workforce of more than 4,000 employees located in approximately 200 medical offices and hospital settings
Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in innovative solutions for aesthetic treatments. Founded in 2009, the company offers a diverse range of products, including Venus Versa, a multi-treatment platform for non-surgical procedures; Venus Legacy, designed for skin tightening and body contouring; and Venus Viva, a customizable skin resurfacing device. Additionally, Venus Concept provides Venus Freeze Plus for anti-aging and non-invasive skin tightening, and Venus Bliss for fat reduction. The company also features advanced hair restoration technologies, including NeoGraft and ARTAS robotic systems, which streamline the follicle harvesting process. Committed to ethical practices and technological advancement, Venus Concept aims to enhance the patient experience in the medical aesthetics industry.
Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for acute and chronic liver diseases, addressing significant unmet medical needs. The company's lead product, OCR-002, is an ammonia scavenger available in both intravenous and oral formulations, specifically targeting hyperammonemia. Ocera recently completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. The company is planning to engage with the FDA to explore potential development pathways for its intravenous program later this year.
AlterG, Inc. specializes in manufacturing and distributing advanced rehabilitation and therapy equipment designed to enhance mobility and accelerate recovery. The company is best known for its Anti-Gravity Treadmill, which utilizes differential air pressure technology to assist patients recovering from lower extremity injuries or surgeries. Additionally, AlterG offers the Stride Smart Gait Analytics treadmill, which enhances anti-gravity therapy, and a Digital Video Monitoring System that facilitates collaboration between patients and therapists for effective rehabilitation. The product line also includes various accessories, such as specialized shorts and mats. Founded in 2004 and based in Fremont, California, AlterG aims to empower individuals by improving their recovery processes, reducing pain during training, and promoting overall health and athletic conditioning. The company's innovative equipment allows users to overcome medical challenges while rebuilding strength and enhancing mobility.
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.
Labcyte Inc. is a specialized laboratory instrumentation company based in San Jose, California, established in 2000. It focuses on acoustic droplet ejection (ADE) technology, which enables the precise dispensing of nanoliter-scale droplets for various life sciences applications, including drug discovery, genomics research, cancer research, and diagnostic testing. The company's flagship product, Echo, utilizes a focused beam of acoustic energy to transfer small volumes of liquids with high accuracy and minimal waste, thereby reducing consumable costs. Labcyte also offers a range of automation systems, laboratory workstations, and control software to enhance laboratory efficiency. As a subsidiary of Beckman Coulter, Inc., Labcyte has expanded its presence internationally, with offices in countries such as Canada, the United Kingdom, Australia, and several others across Asia. The company was previously known as Picoliter Inc. until it rebranded in 2003.
Edgemont’s Management Team and Board of Directors have extensive experience and a proven track record of success in the pharmaceutical industry and the field of life sciences. Click on a link above or scroll down to learn more about the Edgemont leadership team.
Celula, Inc. is a diagnostic testing services company committed to enhancing the accuracy of diagnosing significant diseases, particularly those affecting women, such as gynecologic cancers and non-invasive prenatal diagnoses. The company has developed the Integrated Diagnostic Accuracy (IDA) platform, which combines proprietary and non-proprietary technologies to deliver results that surpass the accuracy of current tests. This platform not only increases the positive predictive value for disease detection but also reduces unnecessary interventions caused by false positives. Results are presented in a customized Integrated Patient Report, aiding decision-making for both patients and physicians. Established in 2005 and headquartered in San Diego, California, Celula also operates a development facility in Chengdu, China, allowing for a capital-efficient approach to product development and commercial expansion. The company operates as a subsidiary of NeoSeq Ltd., enhancing its capacity to innovate in the diagnostic testing space.
ReShape Medical Inc. is a medical device company specializing in non-surgical weight loss solutions for individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30-40. The company offers the ReShape procedure, which utilizes a dual intragastric balloon system combined with a personalized one-year weight loss program, aimed at facilitating weight loss through lifestyle changes. This procedure is designed for adult patients who have not achieved success with diet and exercise alone. ReShape Medical operates through medical weight loss centers and is based in San Clemente, California. Originally founded as Abdominis, Inc. in 2005, the company was rebranded and operates as a subsidiary of ReShape Lifesciences Inc. The broader product portfolio of its parent company includes other minimally invasive devices for treating obesity and metabolic diseases.
Inhibrx, Inc. is a clinical-stage biotechnology company based in La Jolla, California, that specializes in developing a diverse pipeline of novel biologic therapeutic candidates. The company is focused on addressing complex disease biology through its proprietary protein engineering methods, including a single-domain antibody platform. Its key candidates include INBRX-109, a multivalent agonist targeting death receptor 5 for solid tumors; INBRX-105, an antagonist of PD-L1 and conditional agonist of 4-1BB for PD-L1 expressing tumors; INBRX-101, an Fc-fusion protein aimed at alpha-1 antitrypsin deficiency; and INBRX-103, a monoclonal antibody targeting cluster of differentiation 47. Additionally, Inhibrx has preclinical programs such as INBRX-106 and INBRX-111, which focus on oncology and infectious diseases. The company has established collaborations with organizations like Celgene and bluebird bio and has received support from various granting agencies, including the NIH and CARB-X.
InterValve Inc. specializes in developing medical devices for the catheter-based treatment of calcified aortic valve stenosis. Founded in 2008 and based in Plymouth, Minnesota, the company focuses on creating advanced tools for both percutaneous and trans-apical aortic valve replacement procedures. Its flagship product is the V8 Aortic Valvuloplasty Balloon Catheter, designed to optimize the aortic valve area and minimize movement during procedures. This next-generation balloon catheter features a unique figure 8 shape that locks into valve anatomy, enhancing leaflet hyperextension while reducing the risk of annulus over-distension. InterValve operates as a subsidiary of Venus MedTech (HangZhou) Inc. as of June 2017.
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action.
TransEnterix, Inc. is a medical device company that focuses on the research, development, and sale of robotic systems designed to enhance minimally invasive surgery. Its primary products include the Senhance System, a multi-port robotic surgery system that utilizes multiple robotic arms for instrument control and camera operation, and the SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. These systems enable surgeons to perform complex procedures, such as gallbladder removal, with minimal scarring. TransEnterix markets its products directly and through distributors in various regions, including Europe, the United States, Japan, and Taiwan. Founded in 2006, the company is headquartered in Morrisville, North Carolina.
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.
HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.
diaDexus is a biotechnology company specializing in the development and commercialization of diagnostic products for cardiovascular disease. Its primary offering, the PLAC Test, measures Lp-PLA2, an enzyme linked to plaque formation in arteries, providing valuable insights into the risk of coronary heart disease and ischemic stroke. This test is notable for being the only blood test cleared by the FDA for assessing these risks. In addition to cardiovascular diagnostics, diaDexus also develops test kits for a range of other health conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolytes. The company primarily operates in the United States, which constitutes the majority of its revenue, while also maintaining a presence in Europe and other regions worldwide.
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.
Cardiff Oncology is a clinical-stage oncology therapeutics company developing drugs that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers. It has a broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. The company offers its PCM technology at its CLIA/CAP-accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. Cardiff Oncology (formerly known as Trovagene) was founded in 1999 and is headquartered in San Diego, California.
Cerus Corporation is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood cell system is in clinical development.
Tobira Therapeutics, Inc. is a biotechnology company focused on the research, development, and commercialization of antiviral compounds aimed at treating serious infectious diseases. Founded in 2006 and based in Princeton, New Jersey, the company specializes in the development of TBR-652 and TBR-220 antagonists, which are designed for the treatment of HIV/AIDS, hepatitis, and other related infectious conditions. Through its innovative approach, Tobira Therapeutics aims to address critical health challenges associated with these diseases.
DURECT Corporation is a biopharmaceutical company focused on researching and developing innovative medicines for pain management and chronic diseases. The company specializes in creating novel drug delivery technologies, including oral, transdermal, and injectable systems that enhance the efficacy and safety of both small molecules and biologics. Its product pipeline features multiple investigational drug candidates, such as DUR-928, an orally bioavailable small molecule aimed at regulating lipid homeostasis, inflammation, and cell survival, as well as POSIMIR, an analgesic designed to provide extended pain relief after surgery. DURECT also offers the ALZET product line, which includes osmotic pumps for laboratory research, and LACTEL, a range of biodegradable polymers for pharmaceutical applications. The company markets its products through a direct sales force in the United States and a network of distributors in Japan and Europe. Founded in 1998 and headquartered in Cupertino, California, DURECT has established strategic collaborations with several organizations to further its research and development efforts.
IntelliCyt Corporation specializes in developing high-throughput cell- and bead-based screening solutions for the life sciences, particularly in drug and antibody discovery, as well as immunology. Established in 2006 and based in Albuquerque, New Mexico, the company offers the iQue Screener platform, which integrates instruments, software, and reagents for high-content multiplexed analysis of samples in liquid suspension. Its ForeCyt software provides a user-friendly environment for data visualization and analysis, while MultiCyt screening kits supply essential reagents for use with the iQue Screener. IntelliCyt aims to enhance productivity in laboratories by enabling faster and more cost-effective detection and measurement of cells and beads, addressing the needs of pharmaceutical and biotechnology companies, as well as medical centers. The company's innovative technology combines flow cytometry with patented sample processing, allowing assays to be performed significantly faster than traditional methods. IntelliCyt operates as a subsidiary of Sartorius AG, continuing its commitment to advancing research in modern life sciences.
Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, that specializes in developing and commercializing innovative therapies for iron deficiency, nephrology, and cardio-renal conditions. The company's primary product is VELTASSA, a potassium binder used for treating hyperkalemia. Relypsa focuses on creating novel non-absorbed polymeric drugs aimed at addressing significant medical needs in cardiovascular and renal diseases. Established in 2007, Relypsa is committed to advancing its proprietary polymer platform to discover and develop additional therapeutic candidates. As of August 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.
Ceterix Orthopaedics, Inc. develops novel surgical tools for arthroscopic procedures. The Ceterix technology enables surgeons to place stitches in very tight joint compartments, while protecting sensitive surrounding structures such as nerves, arteries and cartilage. This technology has applications in numerous arthroscopic procedures in knees, hips and shoulders.
Ceterix was established in October 2010. The company was founded based on the inventions of Dr. Justin Saliman, an orthopaedic surgeon specializing in sports medicine. Dr. Saliman envisioned improving the outcomes of arthroscopic procedures by enabling surgeons to place suture patterns that today can be done only in open procedures, if at all. Ceterix is based in Menlo Park, California.
Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.
RF Surgical Systems, Inc. is the market leader in the detection and prevention of retained surgical sponges. The RF Surgical Detection System is the preferred solution in more than 1,500 operating rooms, trauma and labor and delivery suites nationwide. Since January 2011, more than 70 hospitals and surgical centers have joined the fast-growing list of care providers using RF Surgical Technology. RF Surgical Systems is based in Bellevue, Washington with R & D facilities in San Diego, California. The advanced technologies used in the RF Surgical Detection System are protected by U.S. patents. Regulatory clearance to market the system was granted by the U.S. Food and Drug Administration in November 2006.
Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes, primarily in Europe. Founded in 1996, the company develops advanced implantable CGM products, including Eversense and Eversense XL, which monitor glucose levels for up to 90 and 180 days, respectively. Using innovative fluorescence sensing technology, these systems are designed to provide high accuracy and stability throughout their extended sensor life. The company aims to empower people with diabetes to manage their condition more effectively and confidently through its CGM solutions, which also include a smart transmitter and a mobile app. A significant portion of Senseonics' revenue is generated from markets outside the United States.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.